Latest News

CORRECTING and REPLACING Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2019

GUILFORD, Conn.–(BUSINESS WIRE)–First paragraph, first sentence of release should read: Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative

Source link

Related posts

Targeting apolipoprotein E could be key to eliminating hepatitis B virus


Discrimination in the Complaints Process: Introducing the Sector Guidance to Address Staff Sexual Misconduct in UK Higher Education


LifeSignals Receives CE Mark for ECG Remote Monitoring Patch


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World